Re-irradiation with or Without Chemotherapy for In-field Local Recurrence among Esophageal Cancer Patients after Initial Definitive Concurrent Chemo-radiotherapy

X. Yang,X. Tian,T. Mei,B. Zou,Y. Liu,X. Zhou,Y. Xu,L. Zhou,J. Xue,J. Wang,Y. Lu,Y. Gong

DOI: https://doi.org/10.1016/J.IJROBP.2020.07.1779

2020-01-01

Abstract:Radiotherapy is the key treatment for non-operative locally advanced squamous carcinoma of the esophagus. In practice, few patients with in-field recurrent esophageal cancer after the primary definitive concurrent chemo-radiotherapy (dCCRT) had possibility of salvage surgery due to poorly general conditions and post-radiotherapy local tissue fibrosis. For patients with good performance status, re-irradiation was one of the potential treatment options. So far, the role of re-irradiation and the impacts of chemotherapy among such patients remain unclear. Between Oct 2008 and Dec 2016, 98 patients with in-field recurrent esophageal squamous cell carcinomas after dCCRT were identified and retrospectively analyzed. Among these patients, 48 patients received re-irradiation alone (re-RT), and another 50 patients received re-irradiation combined with chemotherapy (re-RCT). Statistical analyses were performed with SPSS 26.0. The chi-square test was used to compare the treatment-related complications between the two groups. Survival time was performed using the Kaplan-Meier method. Log-rank test was applied to compare survival rates. Potential prognostic variables were estimated using multi-variate Cox regression model. The p value was considered statistically significant if less than 0.05. In present study, the response rates were 56.3% (27/48) and 72.0% (36/50) in re-RT and re-RCT group respectively (p = 0.104). While, the median progression-free survival (PFS) and overall survival (OS) in re-RT group and re-RCT group were 10.0/15.0 months and 11.3/15.6 months respectively (p = 0.236/0.455). Grade 3 and above toxicities included radiation-induced esophagitis (21.4%), radiation pneumonitis (15.3%), gastrointestinal dysfunction (total 22.4%; 10.4%/34.0% in re-RT and re-RCT group respectively, p = 0.005), neutropenia (total 28.6%; 14.6%/42.0% in re-RT and re-RCT group respectively, p = 0.003), thrombocytopenia (6.1%) and anemia (9.2%). The incidences of treatment-related esophageal fistula in re-RT group and re-RCT group were 12.5% (6/48)/12.0% (6/50) respectively (p>0.05). Re-irradiation was an effective treatment for patients with locally in-field recurrent esophageal cancer after initial dCCRT. Compared with the radiotherapy alone, radio-chemotherapy did not improve PFS and OS among such patients. The incidence of treatment-related esophageal fistula was common, and should be seriously evaluated in clinical practice. Considering the retrospective nature of present study, perspective randomized trials are warranted in future.